Physician profile
Michael L Gross
NPI 1932105285
$6,928.71
in general payments reported to CMS, 2019-2025
32 companies · $628 in 2025
The $628 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $554 · 2021: $777 · 2022: $1,394 · 2023: $1,495 · 2024: $1,454 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,514 · Education: $63.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,513.79 |
| Education | $63.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,639.87 | 2019-2025 | |
| Leo Pharma INC. | $809.29 | 2019-2024 | Adbry |
| Janssen Biotech, INC. | $723.06 | 2019-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $634.64 | 2019-2025 | Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $591.33 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $569.12 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $389.25 | 2019-2025 | |
| Pfizer INC. | $238.74 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $230.50 | 2019-2025 | |
| Galderma Laboratories, L.P. | $182.97 | 2020-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $157.71 | 2020-2022 | |
| Genentech USA, INC. | $147.53 | 2019-2023 | Xolair |
| Incyte Corporation | $114.06 | 2021-2025 | Opzelura |
| Sumitomo Pharma America, INC. | $85.81 | 2025 | Gemtesa |
| Aclaris Therapeutics, INC. | $52.17 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $41.48 | 2023-2025 | Vtama, Hadlima |
| Vyne Pharmaceuticals INC. | $39.18 | 2020 | |
| Verrica Pharmaceuticals INC. | $34.87 | 2023 | Ycanth |
| Sandoz INC. | $28.88 | 2023 | Hyrimoz |
| Arcutis Biotherapeutics, INC. | $19.69 | 2023 | |
| Biofrontera INC. | $19.10 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $18.08 | 2022 | |
| Almirall LLC | $18.06 | 2021 | |
| Mylan Pharmaceuticals INC. | $17.88 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.52 | 2025 | Nuzyra |
| Mayne Pharma Commercial LLC | $17.11 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $16.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.75 | 2023 | Cyltezo |
| Glenmark Therapeutics INC. | $16.00 | 2019 | |
| Ucb, INC. | $15.11 | 2023 | Cimzia |
| Fresenius Kabi USA, LLC | $13.58 | 2024 | Idacio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.